Oxidative stress, testosterone, and cognition among caucasian and mexican-american men with and without alzheimer's disease

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 563-573

  Cunningham, Rebecca L ^a   Singh, Meharvan ^a   O'Bryant, Sid E ^a,b   Hall, James R ^a,b   Barber, Robert C ^a  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Androgens; antioxidants; homocysteine; luteinizing hormone; Mexican American

Indexed keywords

GLUTATHIONE TRANSFERASE; HOMOCYSTEINE; LUTEINIZING HORMONE; SUPEROXIDE DISMUTASE; TESTOSTERONE; GLUTATHIONE S-TRANSFERASE ALPHA; ISOENZYME;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CAUCASIAN; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CORRELATIONAL STUDY; ETHNIC DIFFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICAN AMERICAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; ANALYSIS OF VARIANCE; BLOOD; COGNITION DISORDERS; COMPLICATION; CULTURAL FACTOR; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; COGNITION DISORDERS; COHORT STUDIES; CROSS-CULTURAL COMPARISON; EUROPEAN CONTINENTAL ANCESTRY GROUP; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; LUTEINIZING HORMONE; MALE; MEXICAN AMERICANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; PSYCHIATRIC STATUS RATING SCALES; TESTOSTERONE; TEXAS;

EID: 84901943724     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131994     Document Type: Article

References (74)

1. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60, 762-769. (Pubitemid 43881152)
2. Krasnoff JB, Basaria S, Pencina MJ, Jasuja GK, Vasan RS, Ulloor J, Zhang A, Coviello A, Kelly-Hayes M, D'Agostino RB,Wolf PA, Bhasin S, MurabitoJM(2010) Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab 95, 2790-2799.
3. Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, Yeap BB (2010) Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 95, 3165-3172.
4. Tenover JL (1999) Testosterone replacement therapy in older adult men. Int J Androl 22, 300-306. (Pubitemid 29445885)
5. Morales A, Johnston B, Heaton JP, Lundie M (1997) Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes. J Urol 157, 849-854. (Pubitemid 27066265)
6. Tenover JS (1992) Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75, 1092-1098.
7. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS (2013) Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 173, 1465-1466.
8. Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G (2006) Testosterone therapy in men with Parkinson disease: Eesults of the TEST-PD Study. Arch Neurol 63, 729-735.
9. Cunningham GR, Toma SM (2011) Clinical review: Why is androgen replacement in males controversial? J Clin Endocrinol Metab 96, 38-52.
10. Hildreth KL, Barry DW, Moreau KL, Vande Griend J, Meacham RB, Nakamura T,Wolfe P, Kohrt WM, Ruscin JM, Kittelson J, Cress ME, Ballard R, Schwartz RS (2013) Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 98, 1891-1900.
11. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, BremnerW, Peskind ER, Raskind MA, Craft S (2005) Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 64, 2063-2068. (Pubitemid 40880994)
12. Cherrier MM (2009) Testosterone effects on cognition in health and disease. Front Horm Res 37, 150-162.
13. Tan RS, Pu SJ (2003) A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male 6, 13-17. (Pubitemid 36606396)
14. Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI (2008) Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 20, 213-217. (Pubitemid 351374334)
15. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med 363, 109-122.
16. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy (2004) Testosterone and Aging: Clinical Research Directions, The National Academies Press.
17. Vermeulen A (2001) Androgen replacement therapy in the aging male-a critical evaluation. J Clin Endocrinol Metab 86, 2380-2390. (Pubitemid 32545680)
18. Schrag A, Ben-Shlomo Y, Quinn NP (2000) Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 321, 21-22. (Pubitemid 30417020)
19. Gillies GE, Murray HE, Dexter D, McArthur S (2004) Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav 78, 513-522. (Pubitemid 38906665)
20. Farooqui T, Farooqui AA (2009) Aging: An important factor for the pathogenesis of neurodegenerative diseases. Mech Ageing Dev 130, 203-215.
21. Cunningham RL, Giuffrida A, Roberts JL (2009) Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta. Endocrinology 150, 5539- 5548.
22. Ahlbom E, Prins GS, Ceccatelli S (2001) Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res 892, 255-262. (Pubitemid 32141211)
23. Holmes S, Abbassi B, Su C, Singh M, Cunningham RL (2013) Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells. Endocrinology 154, 4281-4292.
24. Cunningham RL, Macheda T, Watts LT, Poteet E, Singh M, Roberts JL, Giuffrida A (2011) Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. Horm Behav 60, 617-624.
25. Gillies GE, Murray HE, Dexter D, McArthur S (2004) Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav 78, 513-522. (Pubitemid 38906665)
26. O'Bryant SE, Johnson L, Balldin V, Edwards M, Barber R, Williams B, Devous M, Cushings B, Knebl J, Hall J (2013) Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 33, 373-379.
27. O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R (2013) Biomarkers of Alzheimer's disease among Mexican Americans. J Alzheimers Dis 34, 841-849.
28. Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, Groves J, Mayeux R (1996) Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 47, 155-160. (Pubitemid 26243877)
29. Van Den Eeden S, Tanner C, Bernstein A, Fross R, Leimpeter A, Bloch D, Nelson L (2003) Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 157, 1015-1022. (Pubitemid 36628805)
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939- 944. (Pubitemid 14076461)
31. Hafner G, Fickenscher K, Friesen HJ, Rupprecht HJ, Konheiser U, Ehrenthal W, Lotz J, Prellwitz W (1995) Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res 77, 165-173.
32. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95, 2536-2559.
33. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2009) ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 12, 5-12.
34. Kaplan LA, Pesce AJ (1996) The gonads. In Clinical Chemestry: Theory, Analysis, and Correlation, Kazmierczak SC, ed. Mosby-Year Book, St. Louis, MO, p. 894.
35. Mayo Clinic Mayo Medical Laboratories, Test ID: LH Luteinizing Hormone. (LH), Serum, Mayo Foundation for Medical Education and Research, http://www.mayomedicalla boratories.com/test-catalog/Clinical+and+Interpretive/ 8663, Accessed 12-2-2013.
36. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM (2004) Facts and recommendations about total homocysteine determinations: An expert opinion. Clin Chem 50, 3-32. (Pubitemid 38125696)
37. MarlattMW, Lucassen PJ, Perry G, Smith MA, Zhu X (2008) Alzheimer's disease: Cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 15, 199-210.
38. Hortin GL (2006) Homocysteine: Clinical significance and laboratory measurement. Lab Med 37, 551-553. (Pubitemid 44433181)
39. O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS, Doody R (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer's research consortium study. Arch Neurol 65, 1091-1095.
40. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R (2010) A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077-1081.
41. Bowen RL, Isley JP, Atkinson RL (2000) An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol 12, 351-354. (Pubitemid 30156528)
42. Short RA, Bowen RL, O'Brien PC, Graff-Radford NR (2001) Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 76, 906-909. (Pubitemid 32825912)
43. Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS (2002) Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 70, 514-518. (Pubitemid 35222388)
44. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS (2013) Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 173, 1465-1466.
45. Pittman D (2013) FDA splits on safety of Endo's Aveed for Low-T, in MedPage Today, http://www.medpagetoday.com/ Endocrinology/GeneralEndocrinology/ 38566.
46. Clarke T (2013) Panel divided over safety of Endo's testosterone drug, in Reuters, http://www.reuters.com/article/2013 /04/18/us-fda-endohealth- idUSBRE93H17320130418.
47. Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46, 410-413. (Pubitemid 27172090)
48. van den Beld A, Huhtaniemi IT, Pettersson KS, Pols HA, Grobbee DE, de Jong FH, Lamberts SW (1999) Luteinizing hormone and different genetic variants, as indicators of frailty in healthy elderly men. J Clin Endocrinol Metab 84, 1334- 1339. (Pubitemid 30644396)
49. Campbell B, Leslie P, Campbell K (2006) Age-related patterns of urinary gonadotropins (FSH and LH) and E-3-G as measures of reproductive function among Turkana males of northern Kenya. Soc Biol 53, 30-45.
50. Gray A, Feldman HA, McKinlay JB, Longcope C (1991) Age, disease, and changing sex hormone levels in middleaged men: Results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 73, 1016-1025. (Pubitemid 21901140)
51. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, Veldhuis JD (1996) Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad SciUSA 93, 14100-14105. (Pubitemid 26424252)
52. Webber KM, Casadesus G, Bowen RL, Perry G, Smith MA (2007) Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 7, 300-303.
53. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem 279, 20539-20545. (Pubitemid 38623501)
54. Lalonde R (2002) The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev 26, 91-104. (Pubitemid 34130537)
55. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA (2006) Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762, 447-452. (Pubitemid 43344306)
56. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD, Platz EA (2007) Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 92, 2519-2525. (Pubitemid 47037352)
57. Nyante SJ, Graubard BI, Li Y, McQuillan GM, Platz EA, Rohrmann S, Bradwin G, McGlynn KA (2012) Trends in sex hormone concentrations in US males: 1988-1991 to 1999-2004. Int J Androl 35, 456-466.
58. Chern CL, Huang RF, Chen YH, Cheng JT, Liu TZ (2001) Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed Pharmacother 55, 434-442.
59. Huang RF, Hsu YC, Lin HL, Yang FL (2001) Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr 131, 33-38. (Pubitemid 32060619)
60. Ho PI, Ortiz D, Rogers E, Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70, 694- 702. (Pubitemid 35397143)
61. Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB, Rogers E (2003) Folate deprivation induces neurodegeneration: Roles of oxidative stress and increased homocysteine. Neurobiol Dis 14, 32-42. (Pubitemid 37103177)
62. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20, 6920-6926.
63. Mattson MP, Shea TB (2003) Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26, 137-146. (Pubitemid 36183675)
64. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F (2005) Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 82, 636-643.
65. Faux NG, Ellis KA, Porter L, Fowler CJ, Laws SM, Martins RN, Pertile KK, Rembach A, Rowe CC, Rumble RL, Szoeke C, Taddei K, Taddei T, Trounson BO,Villemagne VL,WardV, Ames D, Masters CL, Bush AI (2011) Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: Baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study. J Alzheimers Dis 27, 909-922.
66. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L (2001) Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 56, 1188-1194. (Pubitemid 32405713)
67. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483. (Pubitemid 34441738)
68. Luchsinger JA, Noble JM, Scarmeas N (2007) Diet and Alzheimer's disease. Curr Neurol Neurosci Rep 7, 366-372. (Pubitemid 47422777)
69. Lovell MA, Ehmann WD, Butler SM, MarkesberyWR(1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601.
70. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150, 40-44. (Pubitemid 28146421)
71. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915-919. (Pubitemid 36962976)
72. Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA (1999) Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J Alzheimers Dis 1, 139-145.
73. Chisu V, Manca P, Lepore G, Gadau S, Zedda M, Farina V (2006) Testosterone induces neuroprotection from oxidative stress. Effects on catalase activity and 3-nitro-L-tyrosine incorporation into alpha-tubulin in a mouse neuroblastoma cell line. Arch Ital Biol 144, 63-73.
74. Siddiqui IA, Raisuddin S, Shukla Y (2005) Protective effects of black tea extract on testosterone induced oxidative damage in prostate. Cancer Lett 227, 125-132. (Pubitemid 41169925)